B. Brand

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Pratima Chowdary, Stefan Lethagen, Ute Friedrich et al. · Journal of Thrombosis and Haemostasis · 2015 · 215 citations · Full text

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

Andreas Tiede, B. Brand, R. Fischer et al. · Journal of Thrombosis and Haemostasis · 2013 · 164 citations

Pharmacology, Hematology, Recombinant Factor Viii +6

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia <scp>A</scp>: safety and efficacy

Steven R. Lentz, Mudi Misgav, Margareth C. Ozelo et al. · Haemophilia · 2013 · 83 citations

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A

U. Martinowitz, Jens Bjerre, B. Brand et al. · Haemophilia · 2011 · 51 citations

Immunohematology, Thrombosis, Single N8 Dose +14

Safety and efficacy of turoctocog alfa (NovoEight^®) during surgery in patients with haemophilia A: results from the multinational guardian^™ clinical trials

Elena Santagostino, Steven R. Lentz, Mudi Misgav et al. · Haemophilia · 2014 · 50 citations · Full text